Evidence map›Paper›PMID 42835021›Full record

ArticleFrontiers in immunology2026

Development and evaluation of a dual-target glycoconjugate against

Catherine L Hall, Tom L Flood, Simon Clare, Katherine Harcourt, Emily J Kay, Stephen Baker, Brendan W Wren

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Catherine L HallDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Tom L FloodDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Simon ClareCambridge Institute for Therapeutic Immunology and Infectious Disease, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Katherine HarcourtCambridge Institute for Therapeutic Immunology and Infectious Disease, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Emily J KayDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Stephen BakerASTAR Infectious Diseases Labs (ASTAR IDL), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore.
Brendan W WrenDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Introduction: Shigellosis morbidity and mortality, combined with the increase in multidrug-resistant infections, make Methods: Glycoconjugates were synthesised in Results: When co-produced in Discussion: A novel, conserved

Indexed as

Dysentery, BacillaryGlycoconjugatesO AntigensShigella sonneiShigella VaccinesAnimalsAntibodies, BacterialBacterial ProteinsCarrier ProteinsEscherichia coliFemaleHexosyltransferasesMembrane ProteinsMiceAntibodies, BacterialBacterial ProteinsCarrier Proteinsdolichyl-diphosphooligosaccharide - protein glycotransferaseGlycoconjugatesHexosyltransferasesMembrane ProteinsO AntigensShigella VaccinesbioconjugateglycoconjugateglycoengineeringO-antigenShigellaShigella-specific proteinshigellosisvaccine

Identifiers

PMID42835021
PMCPMC13635124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.